Compound ID | 1439
Class: Bacterial topoisomerase inhibitor
| Spectrum of activity: | Gram-positive |
| Details of activity: | Effective against S.aureus and S. pneumoniae. Discontinued |
| Institute where first reported: | AstraZeneca, UK |
| Year first mentioned: | 2009 |
| Highest developmental phase: | Phase 1 |
| Development status: | Inactive |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/25008769 |
| Citations: |
|